A Phase I Study to Evaluate the Pharmacokinetic and Safety Profile of AZD9496 Following Single Dose Administration of Different Forms and Formulations in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2016
At a glance
- Drugs AZD 9496 (Primary)
- Indications Breast cancer; Male breast cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 07 Nov 2016 Status changed from active, no longer recruiting to completed.
- 10 Aug 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016.
- 10 Aug 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Sep 2016.